Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Quinethazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | CA7 | P43166 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinethazone SCHEMBL29688344 | 1.00 | LMNA (1.00) | LMNAHSD17B10USP2TDP1CA2 | |
| Quinethazone SCHEMBL301310 | 1.00 | LMNA (1.00) | LMNAHSD17B10USP2TDP1CA2 | |
| SCHEMBL13823307 | 0.84 | HSD17B10 (0.73) | LMNAHSD17B10USP2TDP1CA2 | |
| SCHEMBL13815374 | 0.82 | LMNA (0.70) | LMNAHSD17B10USP2TDP1CA2 | |
| Metolazone SCHEMBL1568915 | 0.81 | ALDH1A1 (0.81) | LMNAHSD17B10USP2TDP1CA2 | |
| Mebutizide SCHEMBL13725122 | 0.80 | LMNA (0.64) | LMNAHSD17B10USP2TDP1CA2 | |
| SCHEMBL14394557 | 0.79 | HSD17B10 (0.65) | LMNAHSD17B10USP2TDP1CA2 | |
| Teclothiazide SCHEMBL5324541 | 0.77 | LMNA (0.61) | LMNAHSD17B10USP2TDP1CA2 | |
| Clopamide SCHEMBL28086094 | 0.77 | LMNA (0.68) | LMNAHSD17B10USP2TDP1CA2 | |
| Fenquizone SCHEMBL309550 | 0.74 | HSD17B10 (0.58) | LMNAHSD17B10USP2CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110366414-A | Composition for treating hypertension | 乔治全球健康研究院 | 2019-10-22 | — | — | CN | claimed |
| CN-105025895-B | For treating the 1,3- glyoxalidine -2- 40 thione derivatives of pulmonary hypertension and injury of lungs | 比亚尔-波特拉&Ca有限公司 | 2019-02-26 | — | — | CN | claimed |
| CN-103857440-B | Antimycotic and antibacterium prodrug based on conjugate | 维奥姆生物科学有限公司 | 2018-09-25 | — | — | CN | claimed |
| CN-105407718-A | Coated particles and compositions comprising the same | VYOME BIOSCIENCES | 2016-03-16 | — | — | CN | claimed |
| WO-2008141189-A1 | GHRELIN MODULATING COMPOUNDS AND COMBINATIONS THEREOF | ELIXIR PHARMACEUTICALS, INC. (US) | 2008-11-20 | — | — | WO | claimed |
| EP-3565808-B1 | COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS | ARDELYX INC (US) | 2026-03-04 | — | — | EP | disclosed |
| EP-3574909-B1 | POLYELECTROLYTE MULTILAYER COMPRISING SILVER FOR WOUND HEALING | IMBED BIOSCIENCES INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20260000805-A1 | METHODS AND COMPOSITIONS FOR WOUND HEALING | IMBED BIOSCIENCES INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250375394-A1 | METHODS AND COMPOSITIONS FOR MODIFYING MUCOUS MEMBRANES | ABBOTT NICHOLAS L (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250367188-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-12427138-B2 | Treatment of Meniere's disease | SOUND PHARMACEUTICALS INCORPORATED (US) | 2025-09-30 | — | — | US | disclosed |
| US-12409247-B2 | Methods and compositions for wound healing | IMBED BIOSCIENCES INC. (US) | 2025-09-09 | — | — | US | disclosed |
| WO-2003035039-A1 | METHODS OF TREATMENT USING A GASTRIC RETAINED LOSARTAN DOSAGE | DEPOMED, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003032912-A2 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION, INC. (US) | 2003-04-24 | — | — | WO | disclosed |
| EP-0707446-A4 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF FOR TREATMENT OF NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY | SHAPIRO HOWARD K (US) | 2001-01-10 | — | — | EP | disclosed |
| US-6172069-B1 | CONTROLLING TIME OF ADMINISTERING | G. D. SEARLE & COMPANY | 2001-01-09 | — | — | US | disclosed |
| US-5668134-A | LOMEFLOXACIN HYDROCHLORIDE | G. D. SEARLE & CO. (US) | 1997-09-16 | — | — | US | disclosed |
| US-5668117-A | NERVOUS SYSTEM DISORDERS USING AROMATIC ACID COMPOUNDS | SECANT PHARMA, LLC | 1997-09-16 | — | — | US | disclosed |
| EP-0707446-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF FOR TREATMENT OF NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY | SHAPIRO, Howard, K. (US) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995001096-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF FOR TREATMENT OF NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY | SHAPIRO HOWARD K (US) | 1995-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12427138-B2 | Treatment of Meniere's disease | GPX1, GSR, GPX4 | LMNA 3351/4885HSD17B10 1322/4885USP2 4184/4885 |
| US-20260000805-A1 | METHODS AND COMPOSITIONS FOR WOUND HEALING | PCNA, ARG1, PLOD3 | LMNA 465/4885HSD17B10 4298/4885USP2 3170/4885 |
| US-20250367188-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP3 | LMNA 3715/4885HSD17B10 783/4885USP2 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.